INVESTOR PRESENTATION - love-pharma.com

CSE : LUV

September 2021

INVESTOR PRESENTATION

LOVE PHARMA | INVESTOR PRESENTATION | CSE : LUV 2

Forward Looking StatementsTHIS PRESENTATION IS CONFIDENTIAL AND IS BEING SUPPLIED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED, FURTHER DISTRIBUTED TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE.

This Presentation does not constitute an offer to sell or a solicitation of offers to buy shares or other securities (“Securities”), assets or products of any company or to invest in any fund and is not intended to form the basis of any investment decision. It is not and shall not be construed as a Private Placement Memorandum, and it is not reviewed or regulated by MiFID, AIFMD, or any other financial authority at this stage.

Although reasonable care has been taken to ensure that the facts stated in this Presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this Presentation have not been verified by any company referred to herein or any other person. Accordingly, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this Presentation, and no reliance, should be placed on such information or opinions. Further, the information in this Presentation is not complete and may change. No company referred to herein nor any of their respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this Presentation.

This Presentation is directed only at, and may only be communicated to, (i) persons who are outside the United States within the meaning of Regulation S under the US Securities Act of 1933, as amended (the “US Securities Act”) or (ii) inside the United States to persons who are “accredited investors” as defined in Regulation D under the US Securities Act. No public offering of any securities discussed herein is being made in the United States and the information contained herein does not constitute an offering of securities for sale in the United States and no company is currently intending to register any securities under the US Securities Act. Neither the United States Securities and Exchange Commission nor any securities regulator body of any state or other jurisdiction of the United States, nor any securities regulatory body of any other country or political subdivision thereof, has passed on the accuracy or adequacy of the contents of this Presentation. Any representation to the contrary is unlawful. Persons who do not fall within any of these definitions should not rely on this Presentation or take any action in relation to it. The distribution of this Presentation in other jurisdictions may also be restricted by law, and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions.

Recipients of this Presentation are not to construe its contents, or any prior or subsequent communications from or with any company referred to herein or their representatives as investment, legal or tax advice. In addition, this Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of the relevant company or fund. Recipients of this Presentation should each make their own independent evaluation of the relevance and adequacy of the information in this Presentation and should make such other investigations as they deem necessary. By participating in and/or accepting delivery of this Presentation you agree to be bound by the foregoing restrictions and the other terms of this disclaimer. This Presentation may contain forward-looking statements that reflect current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors.


About UsLOVE Pharma is a future-looking company in an ever-changing industry.

OUR VISION

LOVE Pharma’s vision is to offer innovative products through disruptive technologies, both proven and prospective, that target mental and sexual health, improving the quality of everyday life for all individuals.

OUR MISSION

LOVE Pharma’s mission is to specialize in mental health and sexual wellness by licensing and distributing psychedelic and hemp–infused products. We hold exclusive licenses to produce, market, package, sell, and distribute patent-protected pharmaceutical products throughout Europe, North America, and the United Kingdom.


Executive Summary

• Significant near and mid-term growth catalysts - 7.2% CAGR over the next 10 years (nutraceuticals)

• Investing in sustainable, long-term revenue with proven products, technologies, and established sales performance

• Retail ready products for cross-channel promotion to include DTC, brick & mortar, MLM, closed networks, white labeling, and others

• 6 exclusively licensed technologies

• Experienced, long-term, drug and nutraceutical team

• Domestic and international expansion


A New Age Pharma CompanyLOVE Pharma is committed to offering a fresh and trustworthy perspective to the world of “new age” pharmaceuticals.

LOVE Pharma is currently developing a biosynthetic psilocybin-infused oral strip using its proven and existing intellectual property previously developed for a muco-adhesive strip utilized in our CBD strip.

PSYCHEDELICS NUTRACEUTICALSLOVE Pharma focuses on pharmaceutical-alternative substances with physiological benefits, such as CBD and THC, which can be seen in the initial product launches of Auralief and Bloom.

SEXUAL WELLNESSIntimate enhancement products to increase circulation while providing anti-inflammatory benefits.

Our goal is to enhance both sides of the wellness coin by offering naturally occurring therapeutics backed by scientific research.


0.

17.5

35.

52.5

70.

2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028

Natural Supplement GrowthNorth American Market Size

34.2 B 35.7 B

USD

BIL

LIO

N CAGR

7.2%2017-2028

Source: www.grandviewresearch.com


Pharmaceutical GrowthU.K Market Size

0

13

25

38

50

2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028

USD

BIL

LIO

N CAGR

11.34%2017-2028

12.5 B 13.5 B

Source: www.grandviewresearch.com


Our ProductsProven products made with psychedelics and nutraceuticals to aid in mental and sexual health and wellness.

• Auralief – CannaStrip™ Oral Muco-adhesive Strips

• Bloom – Arousal Gel

• Coming Soon – Psilocybin Infused Oral Strip

• Coming Soon – Male Enhancement Cream

• Coming Soon – ToConceive Gel

• Coming Soon – CBD and THC Biphasic Candies

• Coming Soon – Female Sexual Dysfunction (“FSD”) Supplement

• Coming Soon – Transdermal Nabilone


Initial Product Launch

BLOOMAROUSAL GEL

A topical gel that increases blood circulation and sensitivity. Future versions will be hemp-infused further improving blood circulation and sensitivity.

AuraliefCBD ORAL STRIPS

A discreet cannabis-infused oral strip that speeds-up and enhances the desired effects of THC and CBD.


FEB 2020Closed an initial $2,600,000 CAD in funding

SEPT 2021Listed on the Canadian Stock Exchange: LUV

OCT 2019Signed initial licensing agreements for novel products

APRIL 2020Filed patent in partnership with pharmaceutical company for the delivery of psilocybin in a psychedelic muco-adhesive strip

DEC 2020Signed exclusive licensing partnership with pharmaceutical company

MAY 2021Partnered with Potent Ventures to launch Bloom and Auralief in the US market

MilestonesA look at what we’ve accomplished so far.


Previous and Forecasted Sales$150 million*Arousal Gel Patented Technology

CURRENT CUSTOMERS:

Lifestyles, NHT, and Others

* GLOBAL SALES

$50 million*Male Enhancement Gel

CURRENT CUSTOMERS:

Lifestyles, NHT, and Others

$7.5 million*ToConcieve

CURRENT CUSTOMER:

E.P.T.

$30 millionCBD Mucoadhesive Strip

CURRENT CUSTOMER:

Potent Ventures Inc.

3-year projection$20 millionPsychedelic Psilocybin Strip

3-year projection


Clinical ValidationLOVE Pharma supports all of its products with as much clinical data and research possible.

• Bloom is clinically proven to increase the number, intensity, and speed to orgasm for women. 98% of women reported an overall improvement in sexual experience.

• Auralief is supported by a recent human trial that demonstrated a greater than 30% increase in efficacy and speed to performance of THC and CBD.

• FSD Love Pharma's FSD supplement is supported by a clinical trial demonstrating an overall reported increase in desire, satisfaction, and orgasm within women and is clinically proven to increase sexual satisfaction by 25%.


Canopy Growth

Market Cap: $9 Billion

Share Price: $22.96 CAD

Trading Symbol: TSE:WEED

A world-leading cannabis company based in Smiths Falls, Ontario with an established partnership with Fortune 500 leader, Constellation Brands, and a revenue of $440 million CAD.

Market ComparableStrong public companies that are leading in their respective markets.

MindMed

Market Cap: $1.28 billion

Share Price: $2.92 USD

Trading Symbol: MNMD

A psychedelics company focused on the healing power of the mind that has raised close to $200 million since 2019.

Ro

Market Cap: $308 billion

Share Price: 394.80 CHF

Trading Symbol: SWX: RO

A wellness company based in Basel, Switzerland and founded on sexual health.


Zachary Stadnyk

DIRECTOR AND CHIEF EXECUTIVE OFFICER

Mr. Stadnyk is a corporate finance and advisory professional specializing in taking companies public in emerging markets. Mr. Stadnyk served as the head of corporate finance for The Supreme Cannabis Company from 2014-2018, which raised over $300,000,000 and was later acquired by Canopy growth in 2021 for $435M. Mr. Stadnyk was the founder, director, and chief executive officer of DC Acquisition Corp, a Capital Pool Company ("CPC") that raised an initial $3,000,000 on its IPO and listed on the TSX.V. The issuer completed its qualifying transaction with Kiaro Brands, a leading cannabis retailer, in October 2020, which is targeting $50,000,000 in revenue in fiscal 2022. Mr. Stadnyk also serves on the board of Health Logic Interactive (CHIP –TSXV), an early-stage medical device company.

Team BiosExperienced and specialized team with backgrounds in pharmaceuticals, nutraceuticals, capital markets, and global distribution.

Douglas Taylor

DIRECTOR

Mr. Taylor has over 30 years of extensive experience in managing projects, services, and facilities in the public sector. His previous work included community engagement, strategic planning, business planning, and implementation for a wide range of recreational facilities and services. Implementation encompassed budgeting, financial planning, auditing, and managing human resources. Mr. Taylor’s degree includes two levels of managerial accounting. He has served on the Glenbriar Board as CEO for three years and as president for the past two and a half years.

Mark Tommasi

DIRECTOR

Mr. Tommasi has worked as a senior officer, director, financier, and consultant with over 25 years of experience in corporate development, equity, private equity, and venture capital financing, IPO’s and private placements, marketing, investor relations, and board and committee activities for numerous public and private companies (agriculture, technology, junior exploration, and oil and gas) in both the United States and Canada. Mr. Tommasi has been noted for his ability to help young companies get to the next level.


Tatiana Kovaleva

CHIEF FINANCIAL OFFICER

Ms. Kovaleva is a Vancouver-based finance executive with international and trans-border expertise and credentials as a CPA. Ms. Kovaleva has extensive experience in capital markets, where for over twenty years she served in multiple capacities, including chief financial officer for publicly traded companies such as M Pharmaceutical Inc. and 360 Blockchain Inc. Ms. Kovaleva utilized her specialized executive management experience in public company financial planning and demonstrated a successful track record with timely and accurate financial forecasting, budgeting, reporting, and consolidations, IFRS and GAAP accounting.

Team BiosExperienced and specialized team with backgrounds in pharmaceuticals, nutraceuticals, capital markets and global distribution.

Joshua Maurice

CHIEF OPERATING OFFICER

Mr. Maurice has a 20-year background in consumer goods with a focus on OTC drug and nutraceutical development that includes regulatory clinical research, branding, marketing, advertising, and retail distribution on a global basis. Mr. Maurice has successfully launched retail brands from concept to retail distribution with direct-to-consumer campaigns as well as brick-and-mortar clients like Walmart, CVS, Target, Walgreens, and others. Mr. Maurice’s background in operations, sales, and marketing spans across sectors focusing on profitability and revenue growth.


Kushco

Market Cap: $87.7 millionShare Price: $0.70 USDTrading Symbol: KSHB

Early pioneers in the legal cannabis company, Kushco provides ancillary products and services to legal CBD and cannabis industries. KushCo has sold more than 1 billion units across North America, South America, and Europe.

Previous SuccessSuccessful public companies with a similar business model founded and funded by Stadnyk and Partners Venture Capital Group.

Eupraxia

Market Cap: $49.85 million


Trading Symbol: TSE: EPRX

A clinical-stage biotechnology company leveraging proprietary and innovative delivery technology with the goal of addressing safe durable relief of pain.

The Supreme Cannabis Co.

Market Cap: $205 million


Trading Symbol: SPRWF

Recently acquired by Canopy Growth with a transaction value of $435 million, Supreme operates across 450,000 sq. feet of licensed world-class facilities across Canada.


Capital StructureA strong balance sheet

Common Shares Outstanding 312,169,945

Options for Common Shares nil

Warrants for Common Shares (not listed) 73,626,130

Fully Diluted Shares Outstanding 385,796,075

love-pharma.com

CSE : LUV

Contact:

[email protected]

INVESTOR PRESENTATION - love-pharma.com

Documents

Transcript of INVESTOR PRESENTATION - love-pharma.com